

**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Gerd Burmester  
Mary Crow  
Kimme Hyrich  
Rik Lories  
Iain McInnes  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)

**Disclaimer:** The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

**Copyright:** © 2020 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

*ARD* is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases* (ISSN No: 0003-4967) is distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431. POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o WN Shipping USA, 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.

**Views on news**

- 167** Of mice, men and microbes: the impact of the microbiome on immune responses  
*D S Pisetsky*

**Rheumatoid arthritis**

- 170** Shared decision making in routine clinical care of patients with rheumatoid arthritis: an assessment of audio-recorded consultations  
*E G E Mathijssen, J E Vriezekolk, C D Popa, B J F van den Bemt*

**Spondyloarthritis**

- 176** Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)  
*M Dougados, J C-C Wei, R Landewé, J Sieper, X Baraliakos, F Van den Bosch, W P Maksymowych, J Ermann, J A Walsh, T Tomita, A Deodhar, D van der Heijde, X Li, F Zhao, C C Bertram, G Gallo, H Carlier, L S Gensler, On behalf of COAST-V and COAST-W Study Groups*

- 186** Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged <45 years  
*X Baraliakos, A Richter, D Feldmann, A Ott, R Buelow, C O Schmidt, J Braun*

- 193** Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis  
*U Kiltz, R B M Landewé, D van der Heijde, M Rudwaleit, M H Weisman, N Akkoc, A Boonen, J Brandt, P Carron, M Dougados, L Gossec, M Jongkees, P M Machado, H Marzo-Ortega, A Molto, V Navarro-Compán, K Niederman, P D Sampaio-Barros, G Slobodin, F E Van den Bosch, A van Tubergen, S van Weely, D Wiek, J Braun*

- 202** Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS)  
*G J Macfarlane, O Rotariu, G T Jones, E Pathan, L E Dean*

- 209** Clinical manifestations, disease activity and disease burden of radiographic versus non-radiographic axial spondyloarthritis over 5 years of follow-up in the DESIR cohort  
*C López-Medina, A Molto, P Claudepierre, M Dougados*

**Paediatric rheumatology**

- 217** Factors associated with long-term cardiac dysfunction in neonatal lupus  
*A Saxena, P M Izmirly, R P Bomar, R S Golpanian, D M Friedman, R Eisenberg, M Y Kim, J P Buyon*

- 225** Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis  
*P Y Lee, G S Schuler, S W Canna, Y Huang, J Sundel, Y Li, K J Hoyt, R B Blaustein, A Wactor, T Do, O Halyabar, M H Chang, F Dedeoglu, S M Case, E Meidan, M S Lo, R P Sundel, E T Richardson, J W Newburger, M S Hershfield, M B Son, L A Henderson, P A Nigrovic*

**Systemic lupus erythematosus**

- 232** In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment  
*C Adamichou, D Nikolopoulos, I Genitsaridi, A Bortoluzzi, A Fanouriakis, E Papastefanakis, E Kalogiannaki, I Gergianaki, P Sidropoulos, D T Boumpas, G K Bertias*

- 242** Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus  
*M Grigoriou, A Banos, A Filia, P Pavlidis, S Giannouli, V Karali, D Nikolopoulos, A Pieta, G Bertias, P Verginis, I Mitroulis, D T Boumpas*

- 254** NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus  
*P Linge, S Arve, L M Olsson, D Leonard, C Sjöwall, M Frodlund, I Gunnarsson, E Svenungsson, H Tydén, A Jönsen, R Kahn, Å Johansson, L Rönnblom, R Holmdahl, A Bengtsson*

**MORE CONTENTS ►**

C O P E

Member since 2008  
JM00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>

## Vasculitis

- 262** Clinical symptoms and associated vascular imaging findings in Takayasu's arteritis compared to giant cell arteritis  
*D Michailidou, J S Rosenblum, C A Rimland, J Marko, M A Ahlman, P C Grayson*

## Autoimmunity

- 268** Germline genetic patterns underlying familial rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome highlight T cell-initiated autoimmunity  
*Y Wang, S Chen, J Chen, X Xie, S Gao, C Zhang, Y Zhou, J Wang, R Mai, Q Lin, J Lin, M Matucci-Cerinic, G Zhang, D E Furst*

## Crystal arthropathies

- 276** Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care  
*E Roddy, K Clarkson, M Blagojevic-Bucknall, R Mehra, R Oppong, A Avery, E M Hay, C Heneghan, L Hartshorne, J Hooper, G Hughes, S Jowett, M Lewis, P Little, K McCartney, K R Mahtani, D Numan, M Santer, S Williams, C D Mallen*

## Epidemiology

- 285** Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis  
*X Li, K M Andersen, H-Y Chang, J R Curtis, G C Alexander*
- 292** Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO)  
*C Pettipher, R Benitha*

## Letters

- 301** Use of composite outcomes facilitate core outcome set uptake in rheumatoid arthritis trials  
*J Kirkham, R Christensen, M Boers*
- 302** Rapid induction of clinical remission by immunoadsorption for refractory lupus retinopathy complicated with life-threatening neuropsychiatric lupus  
*G Zhang, X Zhang, Y Chai, S Zang, Y Shi, H Wu*
- 304** Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus  
*K Chatzidionysiou, E Samoli, P P Sfikakis, M G Tektonidou*

- 307** Increased risk of multiple myeloma in primary Sjögren's syndrome is limited to individuals with Ro/SSA and La/SSB autoantibodies  
*J Mofors, A Björk, K E Smedby, M Kvarnström, H Forsblad-d'Elia, S Magnusson-Bucher, P Eriksson, T Mandl, E Baecklund, G Nordmark, M Wahren-Herlenius*

## Electronic pages

- e13** Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching  
*F Cantini, M Benucci*
- e14** Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci  
*B Glinborg, A G Loft, E Omerovic, O Hendricks, A Linauskas, J Espesen, K Danebod, D V Jensen, H Nordin, E B Dalgaard, S Chrysidis, S Kristensen, J L Raun, H Lindegaard, N Manilo, S H Jakobsen, I M J Hansen, D Dalgaard Pedersen, I J Sørensen, L S Andersen, J Grydehøj, F Mehnert, N S Krogh, M L Hetland*
- e15** Some concerns from Turkey  
*E Bilgin, İ Ozarli, L Kılıç, E Ç Bölek, G K Yardımcı, Ö Karadağ*
- e16** Response to: 'Some concerns from Turkey' by Bilgin *et al*  
*Y Kaneko, H Kameda, K Ikeda, T Ishii, K Murakami, H Takamatsu, Y Tanaka, T Abe, T Takeuchi*
- e17** OCTA, a sensitive screening for asymptomatic retinopathy, raises alarm over systemic involvements in patients with SLE  
*Y Mizuno, M Nishide, T Wakabayashi, K Nishida, A Kumanogoh*
- e18** Response to: 'OCTA, a sensitive screening for asymptomatic retinopathy, raises alarm over systemic involvements in patients with SLE' by Mizuno *et al*  
*P Conigliaro, M Cesaro, M S Chimenti, P Triggianese, C Canofari, G Aloe, C Nucci, R Perricone*
- e19** Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine  
*P I Novikov, N M Bulanov, A S Zykova, S V Moiseev*
- e20** Response to: 'Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine' by Novikov *et al*  
*A Kronbichler, D Jayne*

- e21** Disease progression of Takayasu arteritis in two patients treated with tocilizumab  
*C Sanchez-Alvarez, M Koster, A Duarte-García, K J Warrington*
- e22** Paradoxical pulmonary event under tocilizumab treatment for systemic sclerosis-associated usual interstitial pneumonia  
*A L Oliveira, C Ruano, N Riso, J Cepeda Ribeiro, M F Moraes-Fontes*
- e23** Predictive factors of pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids  
*J Herrou, V De Lastours*
- e24** Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis  
*X-D Wu, K-J Hu, B-Y Xiang, W Huang*
- e25** Response to: 'Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis' by Wu *et al*  
*E A M Mahler, M J M Minten, M M Leseman-Hoogenboom, P M P Poortmans, J W H Leer, S S Boks, F H J van den Hoogen, A A den Broeder, C H M van den Ende*